Navigation Links
Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement for Next-Gen Sequencing Software Tools
Date:5/9/2012

BRANFORD, Connecticut and STATE COLLEGE, Pennsylvania, May 9, 2012 /PRNewswire/ --

454 Life Sciences, a Roche Company, and SoftGenetics announced today that the two firms have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe® software.

NextGENe® software is a free standing biologist-friendly software multi-package that is fully compatibility with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling and more. The software package provides additional options for users of 454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite provided with the platforms.

"This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace," states SoftGenetics co-founder John Fosnacht. "SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today's scientific and economic environments."

SoftGenetics offers 30-day trials and no cost web-based training on its genetic analysis software packages. Interested parties may request the software on the company website at http://www.softgenetics.com or via email at info@softgenetics.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in

Chugai Pharmaceutical, Japan. For more information: http://www.roche.com

About SoftGenetics

SoftGenetics, LLC specializes in the development of genetic analysis tools for both research and diagnostic applications. Hallmarks of SoftGenetics software tools are advanced technologies, providing exceptional accuracy, and sensitivity in an easy to use Windows® user interface.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, and 454 SEQUENCING, and are trademarks of Roche.

The name "SoftGenetics," the SoftGenetics logo, NextGENe, and the NextGENe Condensation Tool are trademarks or registered trademarks of SoftGenetics, LLC.

All other product names and trademarks are the property of their respective owners.


For further information please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49-8856-604830
Email: burkhard.ziebolz@roche.com

454 Life Sciences Corporation, a Roche Company
Katie Montgomery
Phone: +1-203-871-2300
Email: katie.montgomery@roche.com

SoftGenetics
John Fosnacht
Phone: +1-814-237-9340
Email: john@softgenetics.com


'/>"/>
SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
2. 2 for 1: Simultaneous size and electrochemical measurement of nanomaterials
3. Kitty Castellini Wins Roche Diabetes Cares Diabetes Heroes Torchbearer Challenge
4. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
5. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
6. Electrochemistry controlled with a plasma electrode
7. Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing
8. Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing
9. Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment
10. Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval
11. China Agri-Business Acquired Management and Operation Rights of Shaanxi Qinfeng Agrochemical Inc. in Xian, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting ... a professor in Harvard University’s Departments of Physics and Astronomy, has been selected for ... of the winning team for the 2015 Breakthrough Prize in Fundamental physics for the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):